DSGN · Design Therapeutics, Inc.
$15.56
-0.38 (-2.38%)
At close · Aug 20
Market Cap
$968.76M
Shares
62.58M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.56
Open$15.69
Day$15.31–15.83
52W close$4.79–15.94
Avg vol 30d504K
Short int6.0M · 9.5% float · 12.0d
Short vol66%
Last earningsApr 28, 2026
DataMar 2021–Aug 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Feb 20, 2027
Est · unconfirmed
· in 26 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 3, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+39%
above
Price vs 50-day avg
+16%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
97%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+34%
trailing
6-month return
+49%
trailing
YTD return
+66%
this year
Relative strength
+38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $11 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.51% of float · ▲ +5.0% MoM · 12.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
136 holders — near 3-yr high, broad support
Squeeze score
87
high risk · 0–100
Fundamentals
EPS growth
−39%
Y/Y
Free cash flow
$-54.6M
Balance sheet
$16.9M
net cash
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+39%
Bullish
Price vs 50-day avg
+16%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
97%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $11 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.51% of float · ▲ +5.0% MoM · 12.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
136 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $16 · 97%
Range high $16
vs 200-day avg +39%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DSGN
this stock
Design Therapeutics, Inc.
|
$968.76M | +65.9% | — | — | 9.5% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DSGN | +8.1% | +33.8% | +49.0% | +27.8% | +65.9% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +10.1% | +30.5% | +37.9% | +25.7% | +54.1% |
Key facts
CIK
1807120
CUSIP
25056L103
13F (30d)
129 filings
128 filers
Visit website
Investor relations